Dyax is a biopharmaceutical company focused on the development and commercialization of products for unmet medical needs while creating value for patients, employees and shareholders.
We are driven by one unifying goal: improving the lives of patients.
Our Areas of Focus:
- KALBITOR® (ecallantide) Discovered and developed by Dyax, KALBITOR is the Company’s commercial product that is approved in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. To find out more and to see Important Safety Information and Full Prescribing Information, including Boxed Warning and Medication Guide, visit www.KALBITOR.com.
- Development Portfolio We are currently developing DX-2930, an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein (pKal) for the prevention of HAE attacks. Additionally, we are expanding upon our expertise in the pKal pathway and have an evolving pipeline of fully human monoclonal antibody drug candidates to potentially address various orphan diseases.
- Licensing and Funded Research Program (LFRP) We have broadly licensed our proprietary phage display technology and have a portfolio of product candidates being developed by our licensees which we refer to as the LFRP. This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties.